Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?

The introduction of highly-active antiretroviral therapy has dramatically reduced human immunodeficiency virus (HIV)-associated morbidity and mortality. Indeed, near-to-normal life expectancy can be expected in HIV infections if antiviral therapy is started before the onset of acquired immune deficiency syndrome (AIDS) or advanced immunodeficiency. Therefore, concomitant diseases are increasingly gaining importance. Coinfection with hepatitis C virus (HCV) is of substantial concern, as HIV is known to accelerate the progression of HCV-related liver disease, which has emerged as a leading cause of death in HIV-infected individuals [1].

Source: International Journal of Antimicrobial Agents - August 23, 2018 Category: Drugs & Pharmacology Authors: Jenny Bischoff, J ürgen K. Rockstroh Tags: Themed Issue: Therapeutics of hepatitis viruses Source Type: research